Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00225797 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain
A Phase 3 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 160
- Enrollment target
NCT00225797: Completed Phase 3 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT00225797 is a Phase 3 study that has completed, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 160 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00225797, a Phase 3 study, has completed, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 160 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the analgesic efficacy and safety of oxymorphone extended release in non-cancer patients with chronic low back pain.
Interventions
- DRUG Oxymorphone Extended Release
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2004-11 |
| Est. Completion | 2005-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00225797
The ClinicalTrials.gov registry entry for NCT00225797 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo USA Inc., a Keenova Therapeutics Company, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oxymorphone Extended Release is the first listed.
NCT00225797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00225797 about?
NCT00225797 is a clinical study titled "Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain". The purpose of this study is to evaluate the analgesic efficacy and safety of oxymorphone extended release in non-cancer patients with chronic low back pain.
What is the current status of trial NCT00225797?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2004-11. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00225797?
The interventions under investigation include: Oxymorphone Extended Release (DRUG).
Who is sponsoring clinical trial NCT00225797?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.